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are	 the	 source	 of	 material	 in	 this	 study.	 	 The	 database	 was	 pseudonymized	 upon	 reception.	
Therefore,	data	cannot	integrally	be	traced	back	to	any	individual.	There	was	therefore	no	need	
to	involve	the	Regional	or	Local	Committee	for	Medical	Research	Ethics	nor	the	Norwegian	Data	
Inspectorate	since	 the	database	 is	properly	secured.	However,	permission	 to	use	 the	data	was	
obligatory.	
Individuals	 between	 20	 and	 79	 years	 of	 age	 are	 the	 subjects	 selected	 from	 the	 database	 and	
categorized	 into	users	of	 insulin	only,	 those	who	received	oral	anti‐glycaemia	agents	only	and	





The	 odds	 ratio	 of	 using	 single	 antidepressants	were	 1.5	 times	 higher	 among	 individuals	who	


















risk	 (OR=1.78,	 95%	 CI:	 1.62‐1.95)	 of	 using	 single	 antidepressants	 compared	 to	 the	 general	
population.	Among	users	of	oral	anti	glycaemic	only,	age	groups	30‐59	had	the	highest	risk	(1.8‐
2.4	times)	compared	to	the	general	population.		The	odds	ratio	for	individuals	who	received	both	




The	 risk	 of	 using	 multiple	 antidepressant	 among	 users	 of	 insulin	 only	 was	 higher	 (2	 times)	
among	age	groups	20‐39	compared	 to	 the	general	population.	 	Among	 individuals	of	oral	 anti	
glycaemic	 only,	 age	 groups	 20‐59	 had	 higher	 significant	 risks	 (2‐3	 times)	 in	 using	 multiple	
antidepressants	 compared	 to	 the	 general	 population.	Whiles	 among	 users	 of	 both	 insulin	 and	
oral	 anti	 glycaemic	 agents,	 individuals	 of	 age	 groups	30‐59	had	 the	 highest	 risk	 (3‐4.5	 times)	
compared	to	the	general	population.	
Regarding	gender,	 the	risk	of	using	multiple	antidepressants	was	higher	 than	the	risk	 in	using	










individuals	 as	 it	was	 for	 the	general	population.	 For	 individuals	using	oral	 antidiabetic	 agents	
only,	 the	 risk	of	using	multiple	antidepressants	versus	single	antidepressants	was	higher	 than	
for	 the	 general	 population.	 The	 reason	 for	 this	 needs	 further	 study.	 Although,	 there	 are	
limitations	of	cross‐sectional	studies	and	secondly,	there	was	no	means	to	adjust	for	factors	as	
























































Normally,	 the	 blood	 glucose	 level	 is	 strictly	 regulated	 by	 insulin,	 a	 hormone	 produced	 by	 the	
pancreas.		The	action	of	insulin	is	to	reduce	the	blood	glucose	level.	When	the	blood	glucose	level	
elevates	 (for	 example,	 after	 meals),	 insulin	 is	 released	 from	 the	 pancreas	 into	 the	 blood	 to	





hyperglycemia	 with	 irregular	 carbohydrate,	 fat	 and	 protein	 metabolism.	 These	 irregularities	
result	from	defects	in	insulin	secretion	and	insulin	action	or	a	combination	of	both[1].		
Diabetes	 mellitus	 symptoms	 include	 unusual	 thirst	 and	 hunger,	 blurred	 vision,	 recurring	 of	
infections,	 delays	 in	 healing	 (cuts	 or	 bruises),	 frequent	 urination	 and	weight	 loss.	 In	 its	most	








at	 a	moderate	 ascension	 [3‐6].	 The	 prevalence	 	will	 continue	 to	 grow	 (within	 all	 age	 groups)	
from	2.8%	in	2000	to	about	4.4%	in	coming	years	(2030)	[3].	Logically	the	study	estimates	the	
number	of	known	diabetes	 to	be	doubled	by	 the	year	2030.	 	 It	was	 in	 turn	estimated	 that	 the	
total	number	of	individuals	having	the	disease	will	rise	from	171	million	in	2000	to	366	million	






The	estimate	 for	diabetes	 (285	million)	 in	2009/2010	 is	 scary	and	 the	mortality	 associated	 is	
about	3.9	million	 [7].	The	number	of	prevalence	 is	 approaching	 the	366	million	 that	was	 first	
estimated	to	be	in	2030.	The	latest	estimate	is	490	million	by	2030	and	the	cost	associated	with	
diabetes	 expenditure	 is	 minimally	 about	 200‐300	 billion	 US	 dollars	 [7].	 The	 principal	
contributing	 factor	 to	 the	 rise	 of	 the	 prevalence	 of	 the	 disease	 is	 from	 older	 people	 in	 the	









of	people	 treated	 for	diabetes	 in	Norway	was	 	110	000	[9],	 this	 is	 in	accord	with	 the	previous	
studies	 mentioned	 above.	 The	 incidence	 rate	 for	 type	 1	 diabetes	 was	 higher	 than	 expected	
among	children	below	15	years	of	age	[9],	despite	previous	research	estimations	as	stable	[10].	
Norway	is	among	countries	with	the	highest	rate	of	incidence	in	regard	to	diabetes	type	1,	and	
the	 prevalence	 of	 diabetes	 type	 2	 has	 also	 been	 increasing	 [5,	 11,	 12],	 and	 the	 latest	 figures	
indicate	that	the	prevalence	will	continue	to	grow,	especially	among	men	[8].	In	Norway	the	total	





understanding	 of	 the	 diseases.	 It	 is	 essential	 to	 understand	 the	 structure	 of	 the	 β‐cells	which	
serves	as	understanding	tool	to	the	functions	of	these	complex	micro‐organs,	and	finally	gives	a	
better	knowledge	about	the	disease.	
The	 β‐cells	 are	 located	 in	 the	 tiny	 cell	 clusters	 (of	 the	 islets	 of	 Langerhans)	 in	 the	 human	
pancreas.	They	are	 the	body’s	 source	of	 the	essential	hormone	 insulin.	The	β‐cells	outnumber	
other	cells	in	the	pancreas.	They	constitute	about	60‐80	percent	in	the	islets	of	Langerhans	[2,	
14‐16]	(Fig.1a).	The	β‐cells	also	release	C‐peptide;	a	polypeptide	fragment	produced	during	the	





equimolar	quantities	 [20‐22]	helps	 to	prevent	neuropathy	 (a	CNS	disease)	 and	other	vascular	
diseases	 of	 diabetes	 [23,	 24].	 The	β‐cell	mass	 can	 also	 be	 estimated	 	 by	measuring	plasma	C‐
peptide	levels	[20].		
The	 β‐cells	 in	 response	 to	 glucose	 stimulus	 can	 produce	 amylin	 (also	 known	 as	 IAPP	 islet	
amyloid	 polypeptide).	 Amylin	 is	 a	 37‐amino	 acid	 polypeptide	 hormone	 that	 is	 simultaneously	
secreted	with	insulin.	[17,	25,	26].	Amylin	is	a	pancreatic	endocrine	hormone	and	contributes	to	























in	 two	phases	(Fig.1b).	An	 immediate	response	 that	release	 the	hormone	 from	the	store	room	
and	a	slower	or	delayed	release	to	support	an	ongoing	insulin	action	or	the	continuation	of	new	
synthesis	 [17,	 30].	 The	 mechanisms	 of	 these	 two	 phases	 differ	 in	 terms	 of	 inner	 membrane	
proteins.	 Syntaxin	 protein	 family	 are	 also	 involved	 in	 the	 first	 phasic	 releases	 of	 insulin	 [31]	
(Fig.1c).	This	response	is	to	some	extent	unusual	in	diabetes	mellitus	[17].	The	release	of	insulin	
involve	Ca2+	 ions	 and	 secretion	 from	vesicle[30].	 The	ATP‐K	 channel	 regulates	 the	membrane	
potential	in	the	β‐cells.		
The	 process	 starts	when	 glucose	 first	 enters	 the	 β‐cells	 via	 a	membrane	 transporter	 (Glut‐2)	
after	 having	 been	 through	 a	 series	 of	metabolism	 by	 the	 enzyme	 glucokinase	 (a	 rate	 limiting	
enzyme)[17]	(Fig.1d).	Then	 followed	by	glycolysis	(glycolytic	generation	of	pyruvate)	 [17,	32].	
The	activity	of	lactate	dehydrogenase	and Lactate	transport	activity	of	plasma	membrane	(in	the	
β‐cell)	 	 play	 an	 important	 role	 in	 determining	 the	 concentration	 of	 	 extracellular	ATP[33‐35].		
Increase	of	extracellular	ADP	leads	to	increased	concentration	of	intracellular	ATP.	This	results	
in	 blockade	 of	 the	 potassium‐ATP	 channels	 and	 ultimately	 leads	 to	membrane	 depolarization	
[17,	36].	Depolarization	opens	 the	voltage	Ca2+	channels	and	hence	 influx	of	Ca2+	 [17,	37].	The	
end	result	is	an	elevation	of	cytoplasmic	Ca2+	concentration.	Together	with	the	aid	of	amplifying	
messengers	(including	di‐acyl‐glycerol,	non‐esterified	arachidonic	acids)	leads	to	the	release	of	




























As	 stated	 earlier,	 the	 regulation	 of	 insulin	 secretion	 strictly	 depends	 on	 the	 plasma	 glucose	
concentration.	The	 control	of	 insulin	 secretion	 from	 the	β‐cells	 and	 the	biological	 and	 cellular	
effects	 on	 target	 tissues	 are	 extremely	 vital	 to	 the	 homeostasis	 of	 glucose.	 The	 pancreas	 can	
sensor	 increase	 in	plasma	 glucose	 concentration	 (example	 after	 a	meal)	 and	 stimulate	 insulin	
secretion,	whereas	a	decrease	inhibits	secretion.	
Amino	acids	(mainly	arginine	and	leucine)	can	also	regulate	insulin	secretions	[17].	Alanine	and	
glutamine	 can	 also	 regulate	 the	 β‐cell	 function	 and	 insulin	 secretion	 [38,	 39].	 Fatty	 acids,	 the	



















fatty	cells	 in	 the	adipocytes	 (yielding	glycerol	 for	 triglyceride	synthesis),	and	 the	 liver	cells.	 In	
the	 liver	 and	 other	 tissues,	 insulin	 increases	 glucose	metabolism	 by	 inhibiting	 glycogenolysis	





extremely	 slow	 in	 the	muscle.	 Insulin	 promotes	 glucose	 transport	 in	 the	muscle	 through	 the	
glucose	transporter	(Glut‐4)	to	increase	glycogen	synthesis	and	glycolysis	[17,	27,	28].		
Insulin	promotes	also	protein	synthesis	by	enhancing	absorbent	of	amino	acids	into	the	muscle.	









The	 insulin	 receptor	 is	 a	 hetero	 tetramer	 consisting	 of	 two	 extracellular	 α‐subunits	 and	 two	




the	 kinase	 receptor	 (β‐unit),	 resulting	 in	 auto‐phosphorylation	 of	 the	 receptor	 on	 tyrosine	
residues	using	ATP	as	phosphate	donor	 [17,	40].	 Insulin	can	stimulate	 the	kinase	receptors	 to	
increase	 the	response	rate	 rather	 than	changing	substrate	affinity.	The	mechanism	 is	not	 fully	
understood,	but	there	is	inhibitory	effects	from	the	α‐unit	on	the	β‐units	[40].	


















The	 glucose	 transporters	 are	 Glut‐1	 and	 Glut‐3	 and	 are	 stereospecific	 to	 D‐glucose.	 The	
regulation	of	the	transporters	is	active	during	brain	development	(Fig.1g).	
Research	has	proven	that	Glut‐1	develops	at	birth	and	grows	rapidly	into	maturity	after	10‐20	
days.	 Glut‐1	 exists	 in	 two	 isoforms	 having	 different	 molecular	 weights	 and	 is	 unevenly	











normally	 between	 21‐30	 days.	 It	 is	 located	mostly	 in	 the	 neurons,	 and	 hence	 is	 the	 neuronal	
transporter	in	the	brain.	
The	glucose	transport	is	passive	in	the	brain	and	requires	no	energy	input.	Therefore,	a	steady‐
state	 transport	 is	 always	 maintained	 by	 glucose	 equilibrium.	 Intracellular	 enzymatic	
contribution	is	also	needed	in	the	transport	processes.	Glucose	transport	depends	somehow	on	
the	availability	of	both	Glut‐1	and	Glut‐3.	The	density	of	Glut‐3	 increases	during	hypoglycemia	
while	 that	 of	 Glut‐1	 remains	 unchanged.	 This	 means	 hypoglycemia	 stimulates	 more	 Glut‐3	
transporters	and	hyperglycemia	are	partly	due	to	down	regulation	of	Glut‐1[41,	42].		













The	 four	 types	of	diabetes	are	diabetes	 type	1,	diabetes	 type	2,	other	specifics	and	gestational	
diabetes.	The	first	 three	are	according	to	etiological	cause.	The	etiological	 types	determine	the	
characteristics	associated	with	diabetes	mellitus	[1].			
"Other	 specific"	 diabetes	 is	 less	 common	 and	 is	 usually	 caused	 by	 drug,	 toxic	 or	 chemical	
induced	 infections,	 diseases,	 immune	 mediated	 diabetes	 and	 genetic	 defects,	 (that	 could	 be	
associated	with	diabetes).		
Gestational	 Diabetes	 occurs	 under	 pregnancy,	 usually	 as	 a	 temporary	 condition.	 	 It	 usually	
affects	about	2‐4	%	of	pregnancies	and	could	also	increase	the	risk	of	diabetes	especially	in	older	
women.	 The	 etiological	 causes	 include	 carbohydrate	 and	 glucose	 intolerance	 resulting	 in	
hyperglycemia	and	insulin	resistance	(during	pregnancy)	[1,	45‐48].	




Type	 1	 diabetes	 results	 from	 the	 body's	 inability	 to	 produce	 insulin.	 Insulin	 should	 be	
administered	by	other	means	(example	by	syringe).	
Damage	to	the	β‐cells	in	the	pancreas	or	serious	diseases	that	can	inhibit	insulin	production	or	






Other	 factors	 like	 insulin	 resistance[17,	 50],	 and	 or	 genetic	 heritability[17,	 53‐55]	 may	 also	
influence	the	clinical	condition	of	the	disease.	In	many		cases,	hereditary	is	strictly	involved	[2].	
Environmental	factors	or	social	conditions	(including	dietary	supplements,	age,	race,	education,	






research	 on	 environmental	 factors,	 and	 concluded	 that	 virus	 infections	 or	 diet	 can	 also	 cause	
type	1	diabetes	in	children	with	known	genetic	risks	[58].	
1.5.2 Treatment	of	type	1	diabetes	





insulin	 subcutaneously,	 where	 it	 enters	 the	 blood	 stream	 and	 become	 available	 for	 the	 cells.	
There	are	many	preparations	of	insulin,	and	these	include	soluble	insulin	for	rapid‐	short	acting	
insulin	 effects,	 partially	 soluble	 and	 insoluble	 insulin	 preparations	 for	 intermediate	 and	 long‐
acting	 insulin	 respectively[17,	 60].	 Some	 patients	 may	 need	 preparations	 of	 short	 and	 long	
acting	of	 insulin,	which	are	suitable	throughout	the	day	and	or	night	prescribed	by	the	doctor.	
Treatment	 of	 Glucose	 control	 alone	 does	 not	 necessarily	 reduce	 the	 risk	 of	 complications	 in	










(Cushing’s	 syndrome	 or	 steroid	 therapy),	 excess	 growth	 hormone	 (pregnancy,	 gestational	
diabetes,	ovary	diseases),	auto	antibodies	to	the	insulin	receptor	mutations	of	insulin	receptor,	
genetic	 obesity,	 hemochromatosis	 (a	 hereditary	 disease	 that	 causes	 tissue	 iron‐accumulation)	
are	all	factors	that	can	cause	insulin	resistance	[2].		
Metabolic	syndrome	comprises	of	factors	that	cause	insulin	resistance.	The	metabolic	syndrome	
sometimes	called	 insulin	 resistance	syndrome	 [60,	62,	63],	 	 (due	 to	symptoms	similarity),	 is	a	
combination	of	medical	disorders	(metabolic	risk	factors)	that	can	increase	the	risk	of	diabetes	





overweight	or	obesity,	physical	 inactivity,	and	genetic	 factors	 [64].	The	mechanism	underlying	
insulin	resistance	and	metabolic	risk	factors	and	or	insulin	resistance	and	obesity	are	not	quite	










because	glucose	control	alone	 (as	a	mono	 therapy)	may	not	be	sufficient	 to	 reduce	 the	risk	of	
macro‐vascular	 in	 diabetes	 [60].	 As	 stated	 under	 SD5	 in	 the	 global	 diabetes	 guidelines,	
individuals	diagnosed	with	diabetes	should	be	offered	with	appropriate	treatment	and	care[70].	
This	 is	 a	 remarkably	 strong	 and	 powerful	 statement	 made	 in	 the	 guidelines.	 	 Appropriate	
treatment	 and	 care	 is	 strictly	 necessary	 and	 aims	 or	 will	 aim	 to	 reduce	 glycaemia,	 blood	
pressure,	and	perhaps	factors	characterized	by	metabolic	syndrome.	Monitoring	complications,	
modifications	 of	 dietary	 and	 exercise,	 medications,	 appropriate	 self‐monitored	 blood	 glucose	
(SMBG)	may	all	be	a	beneficial	treatment	and	care	[17,	60,	61,	71].		





elaborate	 the	 risks	 in	 foot,	 skin,	 and	 dental	 care,	 smoking	 and	 if	 possible	 preconception	 care,	
pregnancy,	and	gestational[75,	76].	
Diet	therapy	(diet	regulation)	for	non‐insulin	dependent	diabetes	is	necessary	because	obesity	is	
also	 a	 risk	 factor	 of	 insulin	 resistance	 and	 β‐cell	 defect.	 Lifestyle	 interventions	 are	 essential	
aspects	of	the	management	of	diabetes	(example	fiber‐rich	food,	reduction	of	fat	intake)	[72,	77].	













variety	 of	 oral	 anti	 hyperglycemic	 agents	 available.	 These	 agents	 differ	 in	 their	 efficacy	 for	
reducing	HbA1c,	FPG,	and	PPG,	 side	effects	 such	as	weight	gain,	bone	 fracture,	and	congestive	








rare	 disorder)[17].	 	 Patients	with	 renal	 or	 hepatic	 diseases	 are	 not	 recommended	 to	 use	 this	
drug.	
Sulfonylureas	synthesized	 from	sulfonic	acid	and	urea	was	 first	developed	 in	 the	1950's.	They	
act	directly	on	the	β‐cells	to	stimulate	insulin	secretion	[17]	provided	there	are	some	β‐cells	left	
[61].	 Their	 mechanism	 of	 action	 is	 on	 the	 potassium	 channel,	 where	 they	 cause	 membrane	
depolarization	by	causing	an	influx	of	Ca2+	ions.	Sulfonylureas	are	well	tolerated	but	could	have	
extremely	severe	adverts	effect	 like	hypoglycemia	(which	could	 last	 longer)	although	modified	
newer	 drugs	 reduce	 these	 risks.	 Another	 unfortunate	 side	 effect	 is	 the	weight	 gain,	 and	 they	
interact	 with	 some	 key	 antibiotics	 [17,	 61,	 83].	 Glipizide,	 glimepirid	 and	 glibenclamide	 are	
among	the	drugs	in	this	group.	
Thiazolidinediones	 reduce	 glucose	 resistance	 in	 the	 muscles,	 fat	 and	 liver	 cells	 by	 the	 act	 of	









pioglitazone	 is	available	 in	Norway.	Rosiglitazone	 is	not	registered	 in	Norway	(unregistered	 in	
2010	due	to	its	increase	of	cardiovascular	risks).	




the	 members	 in	 this	 group.	 Only	 acarbose	 is	 registered	 in	 Norway.	 Adverts	 effect	 includes	
diarrhea	[17,	61,	83,	84].	
Dipeptidylpeptidase‐4	(DPP‐4)‐inhibitors	are	another	drugs	being	actively	used	 these	days	 for	
treatment	 of	 steroid‐induced	 diabetes.	 They	 improve	 glucose	metabolism	 and,	 in	 some	 cases,	
they	 outperform	 metformin	 when	 it	 comes	 to	 dosage	 increasing	 and	 side	 effects.	 DPP‐4	
inhibitors	prevent	 the	 inactivation	of	 glucagon‐like	peptide	1	 (GLP‐1),	which	 is	 responsible	 in	
increasing	 levels	 of	 active	 GLP‐1.	 They	 have	 in	 common	 with	 thiazolidinediones	 in	 that	 they	
increase	insulin	secretion	and	sensitivity.	DPP‐4	also	reduces	glucagon	secretion,	meaning	it	can	
reduce	blood	glucose	 level	 [61,	85,	 86].	 In	Norway,	 sitagliptin,	 vildagliptin	 and	 saxagliptin	 are	
among	the	registered	drugs	in	this	group.	
Combination	 Therapy;	 there	 are	 combination	 drugs	 of	 the	 agents	 mentioned	 above.	 DPP‐4	












since	 these	 factors	 have	 been	 proved	 to	 be	 involved	 in	 diabetes[89‐91].	 Although	 some	







diabetes	 available	 for	 health	 workers	 [73],	 and	 among	 others	 researches	 recommending	
procedures	for	prevention	[93]	and	not	the	least,	hospitals	and	primary	health		procedures	and	
guidelines.	
Some	diabetes	patients	 are	 reluctant	 to	 exercise.	This	 could	be	a	 lack	of	understanding	of	 the	
disease.	 	Motivation,	educational	recommendations,	encouragement,	and	follow‐up	could	be	an	
asset	to	health	care	professionals	that	could	perhaps	better	the	situation.		



























differ	 from	 milder	 symptoms	 to	 more	 severe	 forms,	 including	 symptoms	 like	 delusional	
thoughts,	 somatic	 concerns	 and	 to	 the	worse	 extent,	 suicidal	 ideas	 over	 long	 periods	 of	 time.		
WPA	have	 defined	 the	 term	depression	 (from	medical	 	 view)	 in	 three	 different	meanings;	 i)a	
mood,	a	feeling,	an	emotion,	an	affective	state	ii)	an	indication	of	a	depressive	disorder;	and		iii)	
the	depressive	disorder	itself	[96].		
The	 symptoms	of	depression	 include	both	emotional	 (example	 low	morale,	 less	or	no	 reason)	
and	 biological	 symptoms	 (moral	 retardation	 of	 either	 thought,	 activity	 or	 both	 and	 sleep	
disorders,	appetite	disturbances)[97,	98]	
There	are	two	different	types	of	depression,	namely	unipolar	and	bipolar.	Unipolar	disorder	is	









The	WHO,	 	 Harvard	University	 and	 the	World	Bank	 jointly	 reported	 depression	 as	 the	 fourth	
cause	of	disease	burden	and	accounts	for	3.7%	of	total	disability‐adjusted	life‐years	(DALYs)	in	
1990	 [95].	After	a	decade,	depression	 is	 still	 the	 fourth	 cause	of	disease	burden	and	 this	 time	
accounting	 for	 4.4%	 of	 total	 DALYs[95,	 97].	 Depression	 poses	 the	 largest	 number	 of	 nonfatal	
burden,	with	magnitude	of	circa	12%	of	all	 total	years	 lived	with	disability	worldwide	[95,	97,	
101].	
Risk	of	developing	depression	 is	about	10‐20%	in	 females	whiles	 the	number	 is	 less	 in	males.	
Individuals	under	45	years	are	 likely	 to	be	victimized	than	 individuals	above	45	years	 [94].	 In	





102].	 An	 independent	 	 study	 projected	 the	 burden	 of	 depression	 to	 be	 50%	 higher	 among	
females	than	males[103].	According	to	the	WHO	report,	poverty,	sex,	age,	conflict	and	disasters,	












Earlier	 studies	 focused	on	catecholamine	system	specifically	noradrenalin	as	a	potential	 cause	
for	depression.	Further	research	extended	the	theory	to	include	the	serotonin	system	as	a	cause	
for	 depression.	 Research	 has	 now	 extended	 the	 use	 of	 drugs	 that	 interact	 with	 monoamine	
uptake	 or	 reuptake	 and	 enzymatic	 metabolism	 for	 the	 treatment	 of	 depression.	 Schildkraut	
proposed	 the	monoamine	 theory	 five	decades	ago[105].	 It	 states	 that	depression	 is	a	 result	of	






Series	of	 studies	have	proved	 that	 there	 is	ample	evidence	supporting	 the	monoamine	 theory.	
The	 supporting	 evidence	 from	 the	 studies	 includes	 the	 inhibition	 of	 NA,	 5‐HT	 reuptake	
(improves	 mood),	 inhibition	 of	 MAO	 (yields	 antidepressant	 effect),	 and	 lastly	 reserpine	
(depletes	 monoamine	 storage	 causing	 depression).	 MHPG	 is	 the	 main	 metabolite	 of	







Other	 evidence	 supporting	 the	 theory	 is	 that	 agents	 that	 block	 the	 synthesis	 of	 serotonin	 or	
noradrenaline	are	able	to	antagonize	the	therapeutic	effects	of	antidepressants.		




Antidepressants	 block	 monoamines	 reuptake	 immediately	 on	 administration,	 but	 the	 clinical	
effects	are	not	observed	until	2	weeks	or	longer.	[106,	113‐116].	Scientists	have	tried	to	explain	
the	delay	as	due	to	series	of	reaction	from	receptor	to	gene	transcription	before	results	can	be	
seen[108,	116]	 and	 that	may	 involve	neurons	 and	 synaptic	 activities[117].	Many	 studies	have	
put	 the	 theory	 to	 tests	 through	 urine	 or	 blood	 samples	 for	 irregularities	 of	 biochemical	 in	
depressed	 or	 manic	 patients.	 Some	 studies	 tested	 receptors,	 enzymes,	 transporters	 and	




to	 include	 abnormalities	 of	 second	messenger	 receptors,	 gene	 expressions	 and	 the	 release	 of	











adrenaline	 instead	of	NA.	These	cells	 rectify	 to	 the	pons,	medulla	and	 the	hypothalamus.	They	
are	responsible	in	heart	control.	Other	researches	have	also	confirmed	the	association	between	
NA	 in	 the	 brain	 with	 CNS	 and	 control	 of	 blood	 pressure	 and	 or	 heart	 failure	 [120,	 122].	











raphe	nuclei	 [120,	123].	 It	extends	 from	the	nuclei	 to	a	 lot	of	 locations	 in	 the	cortex	 including	
hippocampus,	 basal	 ganglia,	 the	 limbic	 system	 and	 hypothalamus.	 It	 then	 branches	 to	 the	
cerebellum	medulla	 and	 the	 spinal	 cord.	 The	 5‐HT	 receptors	 	 are	 second	messengers	 in	 a	 G‐
protein	 coupled	 pathway	 with	 the	 exception	 of	 5HT3[120,	 124,	 125].	 5‐HT	 has	 subtypes	 of	











Lots	of	 attention	 is	paid	 to	DA	 in	 the	 last	decades.	DA	has	 few	pathways	 in	 the	brain.	The	DA	
pathway	extends	from	the	substantia	nigra	to	the	corpus	striatum	in	the	negrostriatial	pathway.	




behavioral	 effects[120].	 	 Amphetamine	 causes	 behavioral	 effects	 and	 can	 be	 antagonized	 by	
dopamine	agents.	Dopamine	agents	are	being	used	in	depression	and	psychiatry[120,	129]	and	
almost	 all	 antidepressants	 increase	DA	 activities[117].	Other	 researches	 have	 also	 proved	 the	
pharmacological	 involvement	 of	 dopamine	 in	 depression[130,	 131],	 and	 also	 in	 sleep	







BDNF	 belongs	 to	 the	 neurotrophin	 protein	 family	 of	 growth	 factors	 in	 the	 brain	 and	 the	
periphery	 (specifically	 in	 human	 serum	 and	 plasma).	 BDNF	 has	 roles	 in	 neuronal	 outgrowth,	
differentiation,	synaptic	connectivity,	neuronal	condition	and	have	long	been	recognized	in	the	







BDNF	 has	 also	 been	 reported	 to	 be	 involved	 in	 stress	 and	major	 depression.	 	 Animal	 studies	
have	 shown	 that	 BDNF	 activities	 occur	 in	 patients	 with	 major	 depression	 [134‐137].	 The	
hippocampus	 can	 stimulate	 or	 inhibit	 the	 vasomotor	 center	 and	 have	 therefore	 an	 extremely	
significant	 role	 in	neuroscience.	This	 implies	 that	major	depression	 could	be	 caused	by	BDNF	
degeneration	 (to	 some	 extent)	 in	 the	 hippocampus.	 Scientific	 studies	 have	 shown	 that	
impairment	 BDNF‐TrkB	 receptors	 lead	 to	 poor	 responses	 of	 antidepressant	medication	 [135,	
137].	The	neurotrophic	hypothesis	of	depression	 states	 that	decreased	 levels	of	brain‐derived	
neurotrophic	factors	(BDNF)	are	responsible	for	the	characteristics	seen	in	depressed	patients.	







Adrenal	 steroid	 (cortisol)	 is	 usually	 synthesized,	 released	 by	 and	 under	 the	 regulation	 of	
adrenocorticotropic	 hormone	 (ACTH).	 The	 corticotrophin‐releasing	 hormone	 (CRH)	 from	 the	
hypothalamus	 stimulates	 the	 pituitary	 glands	 to	 release	 ACTH	 (by	 positive	 feedback),	 whiles	
vasopressin	stimulates	ACTH	release	from	the	posterior	glands	by	circulating	glucocorticoids	in	










patient.	 Cortisol	 blood	 level	 reduces	 when	 synthetic	 cortisol	 is	 administered	 by	 a	 normal	
individual.	 Although	 some	 experiments	 have	 shown	 higher	 administered	 doses	 of	
dexamethasone	 to	 suppression	of	ACTH	and	cortisol[98,	138],	 this	 shift	 is	due	 to	 the	negative	
feedback	effect	of	impaired		glucocorticoid	receptors	of	dexamethasone	[138].		
The	hypothesis	states	that	depression	disorders	include	changes	in	the	hypothalamic‐pituitary‐
adrenocortical	 (HPA)	 system.	 Causes	 of	 depression	 in	 some	 depressed	 patients	 might	 result	
from	altered	regulation	of	the	HPA	system	[107,	138,	139].	
CRH	 is	 also	 found	 in	 the	 brain.	 Their	 functions	 in	 the	 brain	 are	 unique	 than	 other	 endocrine	
hormones.	 They	 affect	 behavioral	 effects.	 CRH	 can	mimic	 the	 effects	 of	 depression	when	 they	
enter	the	brain[98,	140].	Experimental	studies	 in	animals	have	supported	behavioral	effects	of	




Treatment	 of	 depression	 and	 other	 monoamine	 neurotransmitter	 diseases	 is	 not	 possible	 by	
direct	 administration	 of	 monoamine	 neurotransmitters.	 This	 is	 because	 the	 monoamine	





in	 the	 brain.	 Research	 has	 shown	 that	 different	mechanisms	may	 increase	 the	 availability	 the	
monoamines.	 These	 include	 blocking	 the	 reuptake	 of	 the	 monoamine	 in	 the	 synapse	 and	 or	
inhibiting	 the	metabolism	of	 the	monoamine	or	 combination	of	both.	The	 fact	 that	 theories	of	
depression	 are	 not	 simple	 has	 led	 to	 a	 wide	 of	 research.	 	 Scientists	 have	 discovered	 a	 lot	 of	
receptors	including	α	and	β	adrenoceptors	(specifically	α2	and	β1	receptors)	that	interact	with	







Scientists	 prefer	 classifying	 antidepressants	 by	 function	 rather	 than	 chemical	 structure	 [147,	
148].	 This	 avoids	 the	misinterpretations	 of	 incorrect	 use	 of	 terminologies	 in	 literatures[148].	
Antidepressant	 agents	 are	 classified	 under	 antidepressant	 (N06A)	 according	 to	 the	 Anatomic	




Monoamine	 reuptake	 inhibitors	 are	 non‐selective	 reuptake	 inhibitors	 of	 the	 monoamines	
notably	 noradrenaline	 or	 serotonin	 (standard	Tricyclic	 antidepressants).	 The	 TCAs	 have	 been	
one	of	the	oldest	antidepressants	available.	 	They	block	the	reuptake	of	amines	by	competitive	
reaction	 for	 the	 binding	 sites	 of	 the	 neurotransmitters.	 They	 interfere	with	 the	 synthesis	 and	
storage	 of	 the	 amines	 in	 the	 synaptic	 vesicles.	 	 They	 also	 prevent	 other	 neurotransmitter	
receptors;	 example	muscarinic	 acetyl	 choline,	 histamine	 and	 5‐HT.	 	 This	 explains	 some	of	 the	
unpleasant	 side	effects	 like	dry	mouth,	urinary	 retention,	blurred	vision	and	 constipation	 [98,	
148].	
Other	non‐selective	monoamine	reuptake	 inhibitors	(serotonin	noradrenaline	reuptake	SNRIs)	
include	 venlafaxine	 and	 duloxetine.	 Drugs	 in	 this	 group	 inhibit	 the	 neuronal	 uptake	 of	 both	
serotonin	 and	 NA.	 However,	 they	 do	 not	 have	 significant	 affinity	 for	 central	 muscarinic,	
histaminic,	or	α‐adrenergic	receptors.	




Selective	 noradrenaline	 uptake	 inhibitors	 (example	 maprotiline,	 reboxetine)	 are	 tricyclic	
norepinephrine‐reuptake	inhibitors	with	anticholinergic	effects.	
Monoamine	 oxidase	 inhibitors	 (MAOIs)	 include	 irreversible,	 non‐competitive	 inhibitors;	 this	
implies	 they	 are	 non‐selective	 to	 either	MAO‐A	 or	MAO‐B	 subtypes	 of	MAO	oxidase	 (example	
phenelzine,	 tranylcypromine	 and	 iproniazid),	 and	 reversible	 MAO‐A	 selective	 inhibitors	
(example	moclobemide).	Their	main	effect	is	to	increase	availability	of	cytoplasmic	monoamines.	
The	mechanism	is	not	well	understood,	but	it	is	believed	they	cause	downregulation	of	both	β‐














diseases	may	 vary	 according	 to	 the	 degree	 of	 illness	 and	management	 of	 disease	 itself	 [154].	
There	have	been	several	researches	on	the	association	or	bilateral	relationships	between	mood	
disorders	 and	 the	 development,	 morbidity	 and	 mortality	 associated	 with	 certain	 medical	
conditions	 or	 diseases	 [94,	 155].	 Researchers	 have	paid	 attention	 to	 diabetes	 since	 300	 years	
ago	[156].		
Anxiety	is	an	emotional	state	usually	caused	by	perceived	danger	that	threatens	the	safety	of	an	
individual.	 The	 symptoms	 may	 include	 generalized	 disorders	 (without	 clear	 reason),	 panic	
disorders	 (with	 panic	 attacks	 associated	 with	 somatic	 symptoms),	 phobias,	 post‐traumatic	
stress	and	excessive	stress	disorder	[157,	158].	Anxiety	is	usually	treated	with	anxiolytics	
Mental	disorders	are	usually	assessed	by	registration	of	patient	symptoms,	behavioral	patterns	
in	 specified	 periods,	 by	 either	 interviews	 or	 questionnaires.	 Studies	 have	 previously	 been	
performed	 on	 anxiety	 among	 diabetes	 patients	 with	 different	 strategies.	 Clinically,	 anxiety	 is	
usually	 assessed	 using	 procedures	 in	 accord	 with	 the	 standard	 criteria	 specified	 in	 the	




of	 “harmonic	 international	 criteria"	provides	 confidentiality	 and	 improves	diagnosis	of	mental	
disorders	made	in	global	research	arena	as	a	common	platform		[159].	
A	 systematic	 study	of	 review	by	Grigsby	 et.al	 estimated	 the	prevalence	of	 generalized	 anxiety	
disorders	among	diabetes	to	be	about	14%,	whiles	up	to	40%	had	elevated	symptoms	of	anxiety,	







and	depression	because	of	diverse	 symptoms	 (and	 coexist	with	each	other	 that	 are	not	 easily	
differentiated)	 [102,	151,	161,	162].	All	 these	studies	 found	a	significant	 relationship	between	
somatic	illness	(including	diabetes),	anxiety	and	depression.	In	a	comparative	studies	of	diabetes	





The	 comorbidity	 of	 diabetes	 and	depression	 becomes	 a	 problem	when	 evidence	 supports	 the	
association	or	risk	factors	between	diabetes	and	depression[156,	164].	Studies	have	enlightened	
the	 difficult	 condition	 (of	 diabetes	 and	 depression)	 to	 be	 severely	 associated	 with	 poorly	
management	 of	 diabetes	 [165‐167].	 Some	 studies	 have	 also	 concluded	 socio‐demographic	
factors	may	also	account	for	the	risk[168].	Other	studies	found	diabetic	patients	with	high	levels	
of	 depressive	 symptoms	 to	 be	 a	 general	 diabetes	 emotional	 distress,	 and	 not	 necessarily	
clinically	related	to	depression[169].	These	studies	suggest	different	methodological	treatments	
instead	 of	 using	 treatments	 for	 depression.	 In	 another	 study	 (of	 assessing	 the	 quality	 of	 life	
among	 diabetic	 patients),	 the	 researchers	 concluded	 that	 depression	 as	 comorbidity	 is	 so	
compelling	 that	 it	 may	 require	 careful	 management.	 This	 is	 because	 depression	 affects	 the	
quality	of	life[163].		
There	are	several	studies	hypothesizing	depression	as	a	risk	 factor	 for	diabetes[170].	Another	
systematic	 review	 estimated	 depression	 in	 type	 2	 diabetes	 to	 be	 17.6%,	 and	 9.8%	 in	 none	
diabetes.	 The	 number	 of	women	 found	 in	 the	 result	was	 higher	 than	men	 (23.8%	 and	 12.8%	










Information	of	dispensed	prescriptions	 from	Norwegian	pharmacies	 (both	public	 and	hospital	
outpatients)	 and	data	 from	 the	Norwegian	 Statistics	 bureau	 (statbank.ssb.no)	 is	 the	 source	 of	
material	as	an	indirect	measure	of	diseases	in	this	thesis.	The	data	are	from	2006.	








Drugs	 prescribed	 on	 the	 blue	 prescription	 are	 ought	 to	 specify	 the	 drug	 indication	 for	 the	
disease	(using	a	reimbursement	code;	§	7	for	diabetes	and	§18	for	psychiatry).		
The	data	include	personal	information	as	age,	month	and	year	of	birth,	sex	and	municipality	of	
residence	 of	 individuals.	 	 Information	 of	 the	 drug	 in	 question	 includes	 Part	 No.,	 number	 of	
packages,	 ATC	 group,	 refund	 points,	 price,	 deductible,	 date	 of	 retrieval.	 	 Lastly,	 information	
about	usage	includes	a	number	of	users	(by	sex,	age,	county	or	health	region),	users	per	1	000	
















consumption	 and	 changes	over	 time.	The	 authorities	use	 the	 registry	on	 a	 statistical	 basis	 for	
quality	assurance	of	drug	consumption,	overall	supervision,	management	and	planning.	









The	 file	 for	 the	year	2006	came	 in	an	ASCII	 format	 (text	 format),	 restructured	by	a	FORTRAN	






Drugs	 that	 fall	 under	 the	 group	 N06A	 (antidepressants)	 in	 the	 ATC	 system	 were	 among	 the	
target	 values.	 A10A	 includes	 all	 insulin	 preparations,	 whiles	 A10B	 includes	 all	 oral	 anti	
glycaemia	agents	registered	in	Norway.	
Insulin	(A10A	in	mono	therapy)	classifies	the	individual	as	type	1	diabetes.	Oral	anti	glycaemia	






2).	 	Most	drugs	under	A10B	require	adequate	and	 functional	β‐cells	 functionality.	 It	 is	 logic	 to	
presume	 the	 individuals	 using	 insulin	 and	 oral	 anti	 glycaemia	 as	 type	 2	 diabetes,	 although	
metformin	 can	 have	 indication	 to	 treat	 women	 with	 polycystic	 ovary	 syndrome	 and	 also	
treatment	of	antipsychotic‐induced	weight	gain.	These	indications	are	not	officially	approved	in	
Norway.	
Only	 individuals	 of	 ages	 20‐79	 are	 in	 the	 analysis.	 Individuals	 in	 the	 database	 were	 then	




Individuals	 of	 ages	 under	 20	 and	 individuals	 of	 ages	 80	 and	 above	 are	 not	 included	 in	 the	
analysis.	 Classifying	 individuals	 below	 20	 years	 of	 age	 into	 diabetes	 and	 related	 conditions	
would	 not	 be	 difficult,	 but	 it	 will	 be	 extremely	 complicated	 in	 regard	 to	 type	 2	 and	 type	 X.	
Secondly;	it	would	not	be	justifiable	to	include	individuals	below	20	years	of	age	with	depressed	
condition	as	a	 result	of	diabetes.	 	 Individuals	of	80	years	and	above	are	not	 included	because	
most	 of	 them	might	 be	 institutionalized.	 It	 would	 be	 difficult	 to	 account	 for	 the	 medications	








main	 work.	 The	 general	 population	 is	 a	 control	 group	 in	 the	 analysis	 (Individuals	 without	
diabetes	medication).	
The	 prevalence	 and	 OR	 (frequency	 and	 percentages)	 were	 both	 calculated	 using	 cross	
tabulation.	 Adjusted	 OR	 and	 confidence	 intervals	 were	 then	 calculated	 with	 binary	 logistic	
regression	analysis	(where	age	and	gender	are	categorical	variables	 in	the	overall	calculation).	






























The	 general	Norwegian	 population	 according	 to	 the	 database	 is	 4,640,219	 cases	 as	 per	 2006.		
124,	649	individuals	received	any	antidiabetic	medication.	Whereby	32,715	individuals	received	





n=3,218,357	 (Male	 =	 1609973,	 Female=1608384).	 	 Table	 1a	 shows	 the	 distribution	 of	 age	
groups	in	the	study	population.	
	
The	 analysis	 compares	 individuals	 on	 diabetes	 medication	 with	 the	 rest	 of	 the	 population	
(without	 diabetes	 medication).	 The	 working	 (selected)	 data	 (20‐79	 years)	 will	 hereon	 be	
referenced	to	as	the	general	population.	Individuals	who	received	insulin	in	mono	therapy	might	
be	assumed	having	type	1	diabetes.	Individuals	using	oral	anti	glycaemic	agents	in	mono	therapy	
are	 likely	 patients	 with	 type	 2diabetes,	 and	 individuals	 receiving	 both	 insulin	 and	 oral	 anti	
glycaemia	agents	in	treatment	are	type	X	diabetes.	
	
Among	 the	 general	 population,	 26,346	 individuals	 (0.8%)	 received	 insulin	 treatment	 in	mono	
therapy	 (constituting	 21.5%	 of	 all	 the	 diabetic	 patients).	 63,176	 (2%)	 received	 oral	 anti‐
glycaemics	 in	mono	therapy	(61.9%	of	 the	diabetic	patients)	and	13,539	(0.4%)	received	both	
insulin	 and	oral	 anti‐glycaemics	 (16.6	%	of	diabetic	patients)	 Illustration	 is	 in	 table	1b.	There	
were	a	total	of	57,957	(56.2%)	male	patients	and	45,104	(43.8%)	female	patients.		
A	 total	 of	 187,090	 individuals	 (5.8%)	 in	 the	 general	 population	 received	 one	 antidepressant,	
whiles	37,970	 (1.2%)	 individuals	 received	multiple	 (two	or	more)	antidepressants	 (Table	1c).		







































Insulin  26346  0.8   21.5 


























Single  187090  5.8   81.7 




















Figures	 3a	 and	 3b	 illustrate	 the	 prevalence	 of	 antidiabetic	 and	 antidepressive	 medications	
according	to	age.	The	values	given	on	the	y‐axis	are	in	absolute	numbers	of	prescription.	




69,	 then	a	 full	 declination.	 Likewise,	 there	 is	 a	 rise	 in	 the	prescription	of	 insulin	 and	oral	 anti	












The	 prescriptions	 of	 antidepressants	 are	 somehow	 different.	 In	 both	 single	 and	 multiple	
antidepressants,	 the	prescription	 increases	with	 increasing	age.	There	 is	a	rapid	 increase	from	























































































































In	 usage	 of	 single	 antidepressant,	 2,305	 (8.9	 %)	 individuals	 (who	 received	 insulin	 in	 mono	
therapy)	 also	 received	 one	 antidepressant	 compared	 to	 5.7	%	 among	 the	 general	 population	
who	also	received	single	antidepressants.		




For	 multiple	 antidepressant	 usage,	 452	 individuals	 (1.9%)	 who	 received	 insulin	 (in	 mono	



















































1.56	 1.52	 1.60	 P<0.001	
Insulin	and	oral	
anti	glycaemia		



















1.84	 1.74	 1.94	 P<0.001	
Insulin	and	oral	






























Fig.3c Risk of Antidepressant usage among Insulin users compared to non-diabetes

































Fig.3d Risk of Antidepressant usage among antiglycaemic users compared to non-diabetes







































Fig.3e Risk of Antidepressant among anti-glycaemic and insulin users compared to non-diabetes




















































Among	 individuals	 who	 received	 insulin	 only,	 6.8%	 (n=1,032)	 males	 received	 single	
antidepressants	 in	 contrast	 to	11.9%	(n=1,273)	 females.	 1.5%	 (n=222)	males	 and	2.4%	 (230)	
females	received	multiple	antidepressants.	Among	individuals	who	received	oral	anti	glycaemic	
only,	 7.5	 %	 (n=2,581)	 males	 and	 14.2%	 (n=3,858)	 females	 received	 single	 antidepressants.	
Whiles	1.9%	(n=606)	males	and	3.7%	(n=897)	females	received	multiple	antidepressants.		








multiple	 antidepressants	 among	 males	 was	 1.70	 (95%	 CI:	 1.48‐1.94).	 Whiles	 females	 had	
OR=1.39	 (95%	 CI:	 1.22‐1.58).	 All	 with	 significantly	 increased	 risk	 compared	 to	 the	 general	
population	(p	value	<	0.001).	
The	 odds	 in	 using	 single	 antidepressants	 among	 diabetic	 patients	 using	 oral	 anti	 glycaemic	
agents	 in	mono	 therapy	was	1.56	 (95%	CI:	 	 1.49‐1.62)	 in	males.	Whiles	 females	had	OR=1.58	
(95%	CI:	 1.53‐1.64).	 In	multiple	 antidepressants,	males	had	 an	OR=1.86	 (95%	CI:	 	 1.71‐2.20).	
Whiles	females	with	OR=1.86	(95%	CI:	1.74‐1.99).	All	OR	were	significantly	increased	(p	value	<	
0.001).	



































20‐29  2970  130  4.4 
 
3.1 
30‐39  4539  280  6.2 
 
4.4 
40‐49  4622  386  8.4 
 
5.9 
50‐59  4660  509  10.9 
 
7.0 
60‐69  4828  523  10.8 
 
7.9 






















20‐29  2874  34  1.2 
 
0.6 
30‐39  4332  73  1.7 
 
0.9 
40‐49  4321  85  2.0 
 
1.3 
50‐59  4253  102  2.4 
 
1.5 
60‐69  4396  91  2.1 
 
1.6 











Tables	 2a	 and	 2b	 illustrate	 the	 outcomes	 from	 the	 analysis	 among	 individuals	 who	 received	
insulin	in	mono	therapy,	single	and	multiple	antidepressants.	
	




glycaemia	 agents)	 shows	 that,	 the	 cases	 in	 single	 antidepressant	 usage	 are	 higher	 within	
diabetes	 individuals	 than	 the	 general	 population.	 	 In	 age	 groups	 20‐29;	 130	 cases	 (4.4	 %)	
compares	to	3.1%	in	the	general	population.	In	age	group	30‐39;	(n=280,	6.2%)	compared	to	4.4	



































Age	group	(in	years)	 OR	 Confidence	Interval	 Pearson		
Chi‐Squared	
20‐29	 1.46	 1.23	 1.75	 P<0.001	
30‐39	 1.50	 1.32	 1.69	 P<0.001	
40‐49	 1.57	 1.41	 1.74	 P<0.001	
50‐59	 1.78	 1.62	 1.95	 P<0.001	
60‐69	 1.58	 1.44	 1.74	 P<0.001	











20‐29	 1.93	 1.40	 2.70	 P<0.001	
30‐39	 1.91	 1.52	 2.41	 P<0.001	
40‐49	 1.61	 1.30	 2.00	 P<0.001	
50‐59	 1.71	 1.41	 2.10	 P<0.001	
60‐69	 1.48	 1.20	 1.82	 P<0.001	












OR	 =	 1.46	 (95%	 CI:	 1.23‐1.75)	 risk	 compared	 to	 the	 general	 population.	 In	 age	 group	 30‐39	
OR=1.5	 (95%	 CI:	 1.32‐1.69),	 whiles	 age	 group	 40‐49	 have	 OR=1.57	 (1.41‐1.74).	 All	 OR	 were	
significantly	 increased	(p	value	<	0.001).The	OR	value	is	somehow	higher	in	the	age	group	50‐
59;	 1.78	 (95%	 CI:	 	 1.62‐1.95),	 then	 the	 value	 falls	 from	 age	 groups	 60‐69	 OR=1.58	 (95%	 CI:		




In	 the	 multiple	 antidepressant	 usage	 among	 users	 of	 insulin	 only,	 the	 OR	 values	 are	 in	
decreasing	order	with	 increasing	 age	 (up	 to	 age	 group	40‐49).	Age	 group	20‐29	had	OR=1.93	
(95%	CI:	1.40‐2.7).	Age	group	30‐39	had	OR=1.91(95%	CI:	1.52‐2.41).	Age	group	40‐49	had	OR=	
1.61	(95%	CI:		1.30‐2.0).	The	trend	changes	from	age	group	50‐59	with	OR=1.71	(95%	CI:	1.41‐















Risk of multiple antidepressant
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20‐29  1098  72  6.6 
 
3.1 
30‐39  3184  335  10.5 
 
4.4 
40‐49  6806  820  12.0 
 
5.9 
50‐59  14402  1679  11.7 
 
7.0 
60‐69  19036  1801  9.5 
 
7.9 






















20‐29  1043  17  1.6 
 
0.6 
30‐39  2942  93  3.2 
 
0.9 
40‐49  6220  234  3.8 
 
1.3 
50‐59  13147  424  3.2 
 
1.5 
60‐69  17605  370  2.1 
 
1.6 













Among	 individuals	 who	 received	 oral	 anti	 glycaemic	 agents	 only,	 the	 trend	 shows	 double	
percentage	in	cases	of	diabetes	compared	to	the	general	population.	The	cases	in	age	group	20‐




still	 high.	 This	 trend	 is	 somehow	 strange	 in	 age	 groups	 70‐79	 (n=1732,	 10.1%)	 where	 the	
prevalence	of	cases	increases	after	declining	at	age	group	60‐69	(Table	3a).	
	




0.9%,	 cases	 in	 40‐49	 (n=234,	 3.8%)	 compared	 to	 1.3%	 is	 also	 high.	 Finally,	 cases	 in	 50‐59	
(n=424,	3.2%)	are	high	compared	to	1.5%	compared	to	the	general	population.	The	trend	then	
changes	by	declining;	at	age	groups	60‐69	(n=370,	2.1%)	also	high	compared	to	1.6%,	and	in	age	

































20‐29	 1.83	 1.44	 2.32	 P<0.001	
30‐39	 2.42	 2.16	 2.71	 P<0.001	
40‐49	 2.32	 2.16	 2.50	 P<0.001	
50‐59	 1.92	 1.82	 2.02	 P<0.001	
60‐69	 1.34	 1.28	 1.41	 P<0.001	








Age	group	(in	years)	 OR	 Confidence	Interval	 Pearson		
Chi‐Squared	
20‐29	 2.25	 1.39	 3.64	 P<0.001	
30‐39	 3.32	 2.70	 4.10	 P<0.001	
40‐49	 3.10	 2.71	 3.53	 P<0.001	
50‐59	 2.33	 2.11	 2.57	 P<0.001	
60‐69	 1.49	 1.34	 1.66	 P<0.001	















In	multiple	 antidepressant	usage,	 the	 risk	also	 increases	with	 increasing	age	until	30‐39,	 then	
declines	again	with	 increasing	age	group.	Age	group	20‐29	had	OR=2.25	 (95%	CI:	 	1.39‐3.64).	
Age	group	had	30‐39	OR=3.32	(95%	CI:	2.70‐4.10).	Age	group	40‐49	had	OR=3.10	(95%	CI:	2.71‐
3.53).	Age	group	50‐59	had	OR=2.33	(95%	CI:	2.11‐2.57).	Age	group	60‐69	had	OR=1.49	(95%	

















20-29 30-39 40-49 50-59 60-69 70-79 80+





















































20‐29  118  16  13.6 
 
3.1 
30‐39  525  78  14.9 
 
4.4 
40‐49  1444  232  16.1 
 
5.9 
50‐59  3250  451  13.9 
 
7.0 
60‐69  4362  531  12.2 
 
7.9 






















20‐29  103  1  1 
 
0.6 
30‐39  446  19  4.1 
 
0.9 
40‐49  1275  63  4.9 
 
1.3 
50‐59  2925  126  4.3 
 
1.5 
60‐69  3925  93  2.4 
 
1.6 























In	 the	analysis	of	multiple	antidepressants	 (table	4.b),	 the	prevalence	of	 cases	 in	 group	30‐39	
(19,	4.1%)	is	almost	five	times	higher	compared	to	0.9%	in	the	general	population.	There	is	no	
difference	in	the	cases	of	age	group	20‐29	(n=1,	1%)	compared	to	the	general	population	(0.6%).	




































20‐29	 4.60	 2.71	 7.81	 P<0.001	
30‐39	 3.86	 3.03	 4.92	 P<0.001	
40‐49	 3.30	 2.86	 3.81	 P<0.001	
50‐59	 2.32	 2.10	 2.57	 P<0.001	
60‐69	 1.76	 1.60	 1.93	 P<0.001	









Age	group	(in	years)	 OR	 Confidence	Interval	 Pearson		
Chi‐Squared	
20‐29	 1.47	 0.21	 10.52	 P=0.703	
30‐39	 4.60	 2.90	 7.29	 P<0.001	
40‐49	 4.18	 3.24	 5.40	 P<0.001	
50‐59	 3.13	 2.61	 3.75	 P<0.001	
60‐69	 1.66	 1.35	 2.04	 P<0.001	










Analytical	 results	 from	 the	 regression	 model	 of	 patients	 using	 both	 insulin	 and	 oral	 anti	
glycaemia	agents,	single	and	multiple	antidepressant	usage	are	in	tables	4c	and	4d.	
 
The	 risk	 in	 using	 single	 antidepressants	 among	 patients	 using	 both	 insulin	 and	 oral	 anti	
glycaemia	agents	decreases	with	increasing	age	group.	The	risk	values	for	age	groups	20‐29	is	
OR=4.60	(95%	CI:	 	2.71‐7.81).	Age	group	30‐39	had	OR=3.86	(95%	CI:	3.03‐4.92).	Age	groups	





In	 multiple	 antidepressants,	 the	 trend	 varies.	 Age	 group	 20‐29	 had	 OR=1.47	 (95%	 CI:	 0.21‐
10.52)	with	 p	 value	0.7	 (not	 significantly	 important).	 The	 risk	 then	decreases	with	 increasing	
age.	Age	group	30‐39	had	OR=4.60	(95%	CI:	2.90‐7.29).	Age	group	40‐49	had	OR=4.18	(95%	CI:	
3.24‐5.40).	Age	groups	50‐59	had	OR=	3.13	(95%	CI:	2.61‐3.75).	Age	groups	60‐69	had	OR=1.66	
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measures	 the	 prevalence	 of	 a	 disease	 at	 a	 time	 (normally	 a	 short	 period	 of	 time).	 This	 study	
deals	 with	 the	 relationship	 between	 diabetes	 and	 depression	 as	 measured	 by	 the	 use	 of	




in	 drawing	 conclusions	 regarding	 causality.	 	 One	 can	 only	 conclude	 there	 is	 a	 mono	 or	
multilateral	 relationships	 between	 the	 cause	 and	 result	 [172].	 However,	 it	 will	 be	 hugely	
beneficial	to	implement	a	follow‐up	(in	a	future	study)	and	perform	other	factors	into	account.	






could	 further	 lead	 to	 a	 systematic	 error	 [172,	 173].	 We	 used	 medication	 as	 an	 indication	 of	
disease,	and	this	gives	an	imprecise	measure	of	the	disease.	Nevertheless,	it	is	unlikely	that	this	









The	 fact	 that	 the	 study	 used	 the	 complete	Norwegian	 population	 seems	 to	 give	 it	 strength	 in	
determining	the	outcomes.		
Selection	 bias	 is	 also	 a	 systematic	 error	 that	 could	 result	 from	 the	 procedures	 of	 selecting	
subjects	 or	 selection	 from	 factors	 that	 influence	 the	 study[172,	 173].	 There	 is	 no	 statistical	
method	that	can	correct	selection	bias.	Selection	of	age	group	from	20‐79	seem	reasonable.	As	
stated	 earlier,	 individuals	 below	 20	 years	 of	 age	 are	 not	 included	 due	 to	 the	 difficulty	 in	
categorizing	them	under	diabetic	type	and	presuming	they	are	suffering	from	depression	related	
illnesses.	 It	 would	 not	 be	 appropriate	 to	 presume	 individuals	 less	 than	 15	 years	 of	 age	 are	
suffering	from	depression.	




received	 insulin	 only,	 (ii)	 those	who	 received	 oral	 anti	 glycaemia	 agents	 only,	 (iii)	 those	who	
received	 both	 insulin	 and	 anti‐glycaemia	 agents	 and	 (iv)	 those	 who	 received	 none	 of	 the	
diabetes	medications	(as	a	control	group).	Secondly	individuals	were	cross	checked	according	to	
whether;	 (i)	 received	 single	 antidepressant,	 (ii)	 received	 multiple	 antidepressants	 or	 (iii)	
received	none.	 	 The	probability	 values	were	 then	 calculated	 and	 adjusted	with	 binary	 logistic	
regression	 (where	 age	 and	 gender	 are	 part	 of	 the	 applicable	 covariates).	 Some	 oral	 anti‐
glycaemia	agents	can	be	used	or	are	in	use	for	the	treatment	of	polycystic	ovary	syndrome	[174‐
176]and	also	 for	 the	 treatment	of	antipsychotic‐induced	weight	gain[177‐179]	 in	children	and	
adolescents[180].	These	indications	are	not	officially	approved	in	Norway.	









Variables	 that	 can	 associate	with	 both	 the	 risk	 factor	 and	 result	 or	 outcome	 are	 confounders.	
Confounder	 can	 interfere	 significantly	with	 results	 in	 epidemiological	 studies	 [172,	 173].	 Age	
and	 sex	 are	 usually	 the	 standard	 confounders.	 Adjusting	 for	 the	 Odds	 ratio	 with	 age	 and	 or	
gender	where	applicable	avoided	these	confounding	factors.		
One	 limitation	 of	 this	 thesis	 is;	 factors	 related	 to	 lifestyle	 could	 affect	 results.	 No	 adjustment	
made	concerning	BMI,	current	income,	physical	activities,	current	smoking,	CHD,	obesity,	other	
chronic	diseases	(such	as	asthma)	or	other	health	problems.	These	problems	could	be	another	
challenge	 in	 a	 follow‐up	 study.	 There	 is	 no	 need	 to	 adjust	 for	 health	 care	 expenditure	 as	 the	
Norwegian	public	health	care	covers	for	all	chronic	diseases.	
Lastly	 it	 is	 difficult	 to	 determine	 whether	 diabetes	 or	 depression	 is	 the	 first	 onset	 disease.	
Logically,	 depression	 or	 diabetes	 may	 be	 an	 onset	 of	 each	 other	 as	 there	 are	 multiple	 of	
evidences	 supporting	 both	 hypotheses.	 Diabetes	 is	 a	 chronic	 disease	 (and	 lasts	 for	 life)	 and	
mood	disorders	swings	(in	episodic).	Some	people	had	gone	through	depression,	recovered,	and	
may	or	may	not	have	depression	later	in	their	life[181].	Unfortunately,	not	everybody	reports	or	
complain	 about	 depression[181]	 and,	 this	 could	 lead	 to	 serious	 conditions.	 Whether	 all	

















Diabetic	 patients	 have	 long	 been	 known	 to	 have	 twice	 the	 risk	 of	 developing	 depression	
compared	 to	 non‐diabetic	 individuals[182,	 183]	 in	 some	 instances	 1.5‐2.5	 times	 the	 risk[184,	
185].	Several	studies	have	suggested	different	factors	playing	role	in	development	of	depression	
among	diabetes	and	vice	versa.	Several	factors	(as	age,	gender,	marital	status,	educational	level	
or	 income)	 are	 also	 	 known	 to	have	an	 impact	 on	depressive	 	 symptoms,	 and	 thus	affects	 the	
quality	 of	 life	 [186,	 187].	 Depression	 itself	 can	 impair	 attributes	 of	 human	 life[181].	 In	 a	





4.3.1 Overall	analysis	 of	antidepressant	usage	among	diabetic	 individuals	 compared	 to	
the	general	population	
In	 the	 usage	 of	 single	 antidepressant,	 the	 OR	 values	 for	 insulin	 individuals	 (possibly	 type	 1	
diabetes)	was	 1.55,	 for	 users	 of	 oral	 anti	 glycaemic	 only:	 1.56	 and	 for	 individuals	 using	 both	
insulin	 and	 oral	 anti	 glycaemic	 agents:	 2.0.	 The	 values	 for	 both	 insulin	 users	 only	 and	 oral	






glycaemic	 only	 and	 to	 those	 who	 received	 both	 insulin	 and	 anti	 glycaemic.	 The	 values	 of	
individuals	using	oral	anti	glycaemic	agents	only	and	for	individuals	using	both	insulin	and	oral	
anti	 glycaemic	 agents	 are	 both	 high:	 1.84	 (95%	CI:	 	 1.74‐1.94)	 and	 2.25	 (95%	CI:	 	 2.04‐2.50)	
respectively.	
The	 overall	 OR	 values	 obtained,	 indicates	 that	 there	 is	 an	 association	 between	 diabetes	 and	
depression.		There	should	be	caution	although,	in	determining	and	finalizing	the	risk	factors	as	
being	 the	 main	 causes	 of	 diabetes	 and	 depression.	 Several	 factors	 related	 to	 human	 lifestyle	
could	contribute	to	the	risks.	 In	a	meta‐analysis,	 	 they	concluded	that	diabetes	 is	 	a	risk	 factor	






onset	 for	 diabetes	mellitus[164,	 190],	 whiles	 in	 some	 studies,	 no	 evidence	 of	 diabetes	 as	 the	




Type	 1	 diabetes	 usually	 debuts	 at	 earlier	 ages.	 Newly	 diagnosed	 person	with	 type	 1	 diabetes	
could	be	 a	burden.	One	 can	 assume	 (on	psychosocial	 factors)	 that	 type	1	diabetes	 individuals	
could	also	become	depressed	(in	the	 long	run)	while	dealing	with	 	management	of	 the	disease	





necessary?	 Does	 their	 depression	 scale	 mandate	 the	 use	 of	 multiple	 antidepressants?	 Is	
depression	the	onset	of	diabetes	type	1?		
The	 risk	 comparison	 in	 the	 regression	 model	 shows	 that	 using	 single	 antidepressants	 was	
significant	 over	 multiple	 antidepressants	 (p<0.001	 vs.	 p=0.67).	 In	 other	 words,	 multiple	
antidepressants	usage	is	insignificant.	These	OR’s	can	be	considered	as	insignificantly	different	
since	the	confidence	intervals	are	overlapping	(Fig.3c).		
Several	 chronic	 diseases	 co‐morbid	 with	 depression[151,	 188].	 Should	 depression	 among	
diabetes	 be	 treated	 with	 caution	 or	 differently?	 Treating	 depression	 sometimes	 needs	 a	
combination	 of	 multiple	 antidepressants	 to	 achieve	 full	 therapeutic	 effects	 [105,	 148]	 and	






The	 risk	 of	 using	 multiple	 antidepressants	 is	 exceptionally	 large	 compared	 to	 the	 single	





different	 since	 the	 confidence	 intervals	 are	 non‐overlapping	 (Fig.3d).	 This	 indicates	 there	 is	
something	 common	 in	 the	 biochemical	 changes	 in	 diabetes	 and	 depression.	 The	 question	 of	
which	illness	is	the	onset	of	what	then	arises.	
The	main	 issue	 is;	 the	 relationships	between	 these	 two	 illnesses	are	co‐morbid	and	may	need	
further	 research	 to	 designate	 the	 mechanism	 associated.	 Controlling	 type	 2	 diabetes	 is	 a	
challenge.	 	 Individuals	 of	 type	 2	 diabetes	 need	 to	 combine	 changes	 in	 life	 style,	 physical	
activities,	 weight	 regulation	 (especially	 where	 the	 individual	 is	 obese)	 to	 achieve	 effect[195,	
196].	It	is	reasonable	to	assume	that	the	stress	involved	in	controlling	life	style	and	medication	




There	 is	usually	poor	 initial	response	to	antidepressant	medication	 in	 treating	diabetes	 type	2	
due	 to	 multiple	 factors[197].	 This	 could	 also	 be	 another	 reason	 for	 using	 multiple	
antidepressants	or	as	part	of	 the	 tailoring	technique	to	suit	 individuals.	Moreover,	obesity	 is	a	
main	 risk	 factor	 among	 many	 type	 2	 diabetic	 patients	 and	 needs	 attention[198]	 and	 obesity	





single	 antidepressant	 are	 2.0	 (95%	 CI:	 1.90‐2.11).	 The	 odds	 for	multiple	 antidepressants	 are	
2.25	(95%	CI:	2.04‐2.50).	These	values	are	higher	compared	to	the	general	population.		
Individuals	 using	 both	 insulin	 and	 oral	 anti	 glycaemic	 agents	may	 be	more	 related	 to	 type	 2	
diabetes	 since	 insulin	has	proven	 to	be	 successful	 in	 combination	with	oral	 agents,	when	oral	
agents	alone	is	inadequate	or	fades	during	therapy[61,	200].	Although,	some	individuals	of	type	
1	 diabetes	 could	 also	 start	with	 oral	 anti	 glycaemia	 agents	when	necessary[201]	majority	 are	









might	 help	 combat	 depression	 among	 diabetic	 patients.	 Diabetes	 self‐management	 is	 tedious	
and	 need	 commitment	 of	 time[203],	 which	 could	 be	 one	 of	 the	 causation	 of	 stress[204]	 and	
depression	as	a	co‐morbid	to	the	disease[188].	Diabetic	patients	using	both	insulin	and	oral	anti‐
glycaemia	 agents	 may	 have	 a	 lot	 to	 deal	 with	 the	 issue	 of	 self‐management[203].	 Evidence	
suggests	 depression	 could	 also	 be	 a	 cause	 from	 ineffective	 diabetes	 self‐care[165].	 Although,	
there	are	multiple	of	factors	involved	in	diabetes	self‐	management;	good	self‐care[205]	can	still	
be	 achieved	 through	 interventions	 and	 it	 is	 considered	 as	 an	 important	 part	 of	 clinical	
management	of	diabetes[206].		
It	 is	still	uncertain	why	some	individuals	use	multiple	antidepressants,	while	others	use	only	a	
single	 antidepressant.	 Although	 individuals	 respond	 differently	 to	 medications,	 it	 will	 be	








4.3.2 Analysis	 of	 antidepressant	 usage	 among	 diabetic	 individuals	 compared	 to	 the	
general	population	within	age	groups	
The	risk	of	using	single	antidepressant	increases	with	increasing	age	groups	and	declines	from	
age	 group	60‐69	 among	users	 of	 insulin	 only	 (type	1	diabetes).	 The	 risk	was	 also	high	 in	 age	






to	 treat	 depression	 among	 individuals	 using	 insulin	 only	 (diabetes	 type	 1).	However,	 the	 risk	
was	high	among	younger	age	groups	especially	age	group	20‐	29.	Other	studies	have	also	found	
depression	to	be	associated	with	type	1	diabetes[213].	A	Canadian	national	survey	conducted	a	






glycaemia	 control	 and	 microvascular	 diabetes	 complications[215].	 The	 complications	 can	
worsen	 from	 late	 adolescent	 life	 and	 affect	 their	 adulthood[215].	 Another	 explanation	 of	 high	
prevalence	 among	 younger	 age	 group	 is	 still	 the	 problem	 of	 obesity.	 The	 trend	 of	 the	 risk	
changes	 again	 at	 age	 group	 50‐59.	 	 Although	 individuals	 in	 these	 age	 groups	 might	 also	 be	
influenced	by	some	factors	as	less	physical	activities,	one	cannot	rule	out	other	chronic	illnesses	
(as	asthma	which	is	not	regarded	during	the	selection	of	individuals	in	this	study).	


















significant	 (among	 all	 age	 groups)	 in	 single	 antidepressants	 usage,	 while	 in	 multiple	
antidepressants	 the	 risk	 was	 significant	 in	 some	 age	 groups.	 The	 OR’s	 can	 be	 considered	










depressive	 disorders[217].	 This	 might	 also	 be	 one	 of	 the	 reasons	 for	 seeing	 usage	 of	
antidepressants	in	these	age	groups.	Obesity	in	diabetes	can	be	controlled	with	body	weight	loss	
and	increased	physical	activities.	These	are	some	of	the	important	factors	to	improved	glucose	
tolerance	 and	 insulin	 sensitivity[218].	 	 There	 is	 evidence	 supporting	 previous	 history	 of	
depression	might	 onset	 depression	 among	 diabetes	 individuals	 [219]	 and,	 can	 also	 accelerate	
the	risk	of	diabetes	type	2	compared	to	individuals	without	prior	history		[184].	
	





In	multiple	 antidepressant	 usage,	 the	 increasing	 risk	 propensity	 starts	 from	 age	 group	 30‐39	
OR=4.60	 (95%	CI:	2.90‐7.29)	and	decreases	with	 increasing	age	group.	There	 is	no	 significant	
risk	 among	 the	 age	 group	 20‐29.	 The	 risks	 among	 age	 groups	 60‐69	 and	 70‐79	 are	marginal	
compared	 to	 other	 age	 groups.	 This	 is	 still	 significantly	 high	 and	 confirms	 the	 findings	 of	 the	
English	 longitudinal	 study	whereby	 diabetes	 is	 also	 associated	with	 depression	 in	 individuals	
over	 50	 years	 of	 age[220].	 The	 study	 predicted	 sociodemographic,	 lifestyle,	 and	 other	 clinical	
factors	being	part	of	the	risk	factors.		
Comparison	of	risks	of	single	and	multiple	antidepressants	indicates	the	OR’s	can	be	considered	
significantly	different	 in	 the	 confidence	 intervals	where	 the	points	are	non‐overlapping	 in	 age	
group	50‐59	(Fig.3h).	One	could	argue	that,	perhaps	the	total	number	of	diabetic	 individual	 in	
age	 groups	 50‐59	 are	 less,	 but	 in	 Fig.3b	 the	 turning	 point	 of	 prescriptions	 of	 antidepressants	
starts	at	age	group	50‐59.	
	The	risks	are	also	significantly	higher	in	individuals	using	both	insulin	and	oral	anti	glycaemic	
agents	 compared	 to	 individuals	 using	 insulin	 only	 (type	 1)	 and	 to	 those	 using	 anti	 glycaemic	
agents	 only	 (types	 2).	 One	 explanation	 could	 be	 that,	 even	 though	 the	 use	 of	 insulin	 and	 oral	
anti‐glycaemia	 agents	 betters	 the	 situation	 or	 help	manage	 the	 illness,	 there	 could	 be	 tedious	









be	 associated	 with	 poor	 diet	 and	 or	 poor	 metabolic	 control[183],	 and	 non‐adherence	 to	
medication[222].	The	disease	burden	can	be	reduced	with	adherence	to	better	medication[59].	









among	men	 than	women,	 even	 though	 there	 are	more	women	with	 the	 disease	 than	men[3].	
Depression	is	also	related	to	gender	among	diabetes[161]	and	to	general	depression.	
Among	 individuals	 using	 insulin	 only	 (type	 1	 diabetes),	 the	 risk	 for	 males	 in	 using	 single	








For	 individuals	 using	 both	 insulin	 and	 oral	 anti	 glycaemic	 agents,	 the	 risk	 of	 using	 single	
antidepressants	 among	 males	 was	 OR=2.06	 and	 for	 females	 OR=1.98.	 The	 risk	 of	 multiple	
antidepressants	usage	for	males	was	OR=2.33	and	for	females	OR=	2.23.	As	the	values	speak	for	
themselves,	the	differences	in	risk	values	were	remarkably	little.	
As	 seen	 above,	 the	 difference	 in	 risks	 among	men	 and	women	was	 substantial	 in	 individuals	











The	 co‐morbidity	 of	 diabetes	 and	 depression	 was	 long	 identified	 by	 a	 British	 scientist	 many	
years	 ago[216].	 The	 prevalence	 of	 diabetes	 is	 increasing	 and	 likewise	 the	 prevalence	 of	
depression	among	diabetic	patients[7,	225].	Both	minor	and	major	depression	in	diabetes	is	also	
related	 to	mortality[226].	 There	 are	 several	 publications	 regarding	 the	 relationships	 between	
diabetes	and	depression.	Some	predict	and	theorizes	diabetes	to	be	the	risk	factor	of	depression,	














risk	 factor	 for	developing	diabetes	 [228].	Assuming	these	 individuals	received	antidepressants	
for	 treatment	 (during	 the	 follow‐up)	 could	 also	 have	 influenced	 the	 outcome.	 Some	
antidepressants	 have	 the	 tendency	 to	 increase	 the	 risk	 of	 hyperglycemia	 or	 interfere	 with	
glucose	homeostasis	(especially	olanzapine,	sertraline	and	some	Tricyclic	and	SSRIs)[208,	209,	












that	 include	 psychosocial	 and	 behavioral	 factors.	 Factors	 such	 as	 physical	 inactivity,	 elevated	
BMI,	smoking,	obesity	and	sleep	disorders	and	physiological	or	hormonal	factors	(such	as	stress)	
could	 all	 be	 associated	 with	 depression[185,	 232].	 Depressed	 individuals	 may	 have	 all	 these	




levels)	 and	 could	 lead	 to	 diabetes	 type	 2	 symptoms[216].	 Depression	 in	 diabetes	 is	 also	
associated	 with	 or	 it	 is	 due	 to	 hyper‐secretion	 or	 elevated	 levels	 of	 IL‐6,	 TNF‐α,	 and	 other	











eliminate	 the	burden	of	 treatment	and	 the	disease	 itself	as	being	risk	 factors.	The	burden	and	
psychological	 distress	 can	 also	 be	 explained	 with	 the	 findings	 of	 other	 studies,	 where	 they	
confirmed	 diabetes‐specific	 emotional	 distress	 as	 being	 predictors	 of	 depression	 [202,	 234].	
Other	studies	have	also	hypothesized	that	psychosocial	factors	are	key	predictors	in	the	diabetes	
care	(in	both	children	and	adults)[235].	Psychosocial	factors	and	diabetes	care	can	be	improved	






All	 these	 factors	 together	 could	 improve	 the	quality	 of	 life	 [186,	 239,	 240].	Obesity	 cannot	be	









depression.	 The	 hypothesis	 briefs	 the	 axis	 of	 depression	 should	 be	 perceived	 as	 a	 result	 of	
dysfunctional	astroglial	bioenergetics,	a	cerebral	hypoglycometabolic	syndrome.	Depression	is	a	
diverse	disease	and	should	not	be	viewed	as	a	specific	biochemical	disorder.	Depression	should	




the	 system	 (glucose	 metabolism)	 is	 less	 affected,	 and	 if	 not	 none,	 includes	 the	 ability	 and	
function	 of	 the	 neurons.	 Glucose	 transporters	 are	 present	 in	 the	 blood	 brain	 barrier	 (in	
astroglia).  The	 target	 of	 insulin	 secretion	 in	 the	 brain	 is	 the	 astroglial	 and	 not	 the	 neurons.	













antidepressant	 to	 diabetic	 patients.	 Secondly	 clinicians	 can	 consider	 when	 to	 use	 single	 or	
multiple	antidepressants	usage.	Thus,	 antidepressants	 that	 can	cause	weight	gain	and	or	have	
the	potential	risks	of	causing	irregularities	on	glycaemia	should	be	reassessed.	
Both	 health	 personnel	 and	 patients	 may	 work	 together	 to	 improve	 diabetic	 patients	 health	
through	 interventions[246]	 that	 might	 also	 have	 a	 greater	 impact	 on	 perceived	 heath	 of	
individuals.	Perceived	health	measures	subjective	health	of	individuals.	It	deals	with	the	general	





This	 thesis	 has	 drawn	 a	 variety	 of	 attention	 on	 the	 use	 of	 antidepressants.	 There	 are	 several	
researches	on	the	linkage	between	diabetes	and	depression.	The	findings	in	this	thesis	have	also	
strengthened	 the	 result	 of	 other	 studies	 with	 a	 significant	 association	 between	 diabetes	 and	
depression.	There	is	still	in	need	of	research	to	resolve	the	bidirectional	development	of	diabetes	
and	 depression	 especially	 the	mechanistic	 direction	 of	 the	 co‐morbidity.	 A	 follow	 up	 study	 is	









This	 thesis	 studied	 the	 usage	 of	 single	 and	 multiple	 antidepressants	 among	 patients	 with	
diabetes.		The	findings	in	this	thesis	indicate	that,	the	use	of	single	antidepressants	is	higher	than	
the	use	of	multiple	antidepressants	among	diabetic	individuals	as	it	is	in	the	general	population.	
There	was	a	 significant	 risk	of	using	both	 single	 and	multiple	 antidepressants	 among	diabetic	
individuals	compared	to	non‐diabetes	in	the	general	population.			
In	the	overall	 findings	and	compared	to	the	general	population,	 there	was	no	difference	 in	the	
risk	of	using	single	and	multiple	antidepressants	within	patients	using	 insulin	only.	There	was	
also	 a	 substantial	 risk	 of	 using	 single	 antidepressants	 among	 patients	 using	 oral	 anti	 diabetic	
agents	 only	 compared	 to	 the	 general	 population	 and	 highly	 significant	 risk	 of	 using	 multiple	
antidepressants	compared	to	the	general	population.	The	difference	was	significant,	 i.e.	among	
these	patients	 there	was	 a	higher	use	of	multiple	 antidepressants	 than	 single	 antidepressants	
compared	 to	 the	 general	 population.	 Patients	 using	 both	 insulin	 and	 oral	 antidiabetic	 agents	








antidiabetic	 only,	 the	 risks	 of	 using	 both	 single	 and	 multiple	 antidepressants	 decreases	 with	
increasing	age	group.	However	the	risk	is	higher	among	younger	adults	compared	to	the	general	
population	and	lower	among	individuals	from	60	years	and	above.		The	risk	of	using	both	single	
and	 multiple	 antidepressants	 is	 also	 higher	 among	 young	 adults	 using	 both	 insulin	 and	 oral	
antidiabetic	agents	and,	decreases	with	increasing	age	group.	
The	risks	of	using	multiple	versus	single	antidepressants	were	similar	between	men	and	women.	







Finally	 the	 findings	 confirm	 the	 relationship	 between	 diabetes	 and	 depression	 shown	 in	
previous	studies,	but	these	results	cannot	be	used	to	judge	whether	diabetes	increases	the	risk	
of	depression	or	vice	versa.	Further	 research	 is	 strongly	 recommended,	especially	a	 follow	up	
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